GlassScriptPhysician profile
Beverly Wood
NPI 1407812712
$2,530.15
in general payments reported to CMS, 2019-2025
32 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $196 · 2021: $736 · 2022: $536 · 2023: $400 · 2024: $50.53 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.66 | 2019-2023 | Lo Loestrin Fe |
| Lilly USA, LLC | $343.80 | 2022-2025 | Zepbound |
| Astellas Pharma US INC | $232.24 | 2022-2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $223.25 | 2021 | |
| Therapeuticsmd, INC. | $158.23 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $124.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2021 | |
| Coopersurgical, INC. | $97.47 | 2019 | |
| Mayne Pharma Commercial LLC | $89.20 | 2022-2023 | |
| Hologic Sales and Service, LLC | $72.63 | 2021-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Organon LLC | $68.59 | 2021-2024 | |
| Vertical Pharmaceuticals, LLC | $65.19 | 2019-2020 | |
| Pfizer INC. | $51.09 | 2022-2025 | |
| Myovant Sciences INC. | $46.83 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $45.87 | 2023 | Myfembree |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $36.37 | 2021 | |
| Exeltis, USA INC. | $32.42 | 2024-2025 | Slynd |
| Millicent US INC | $30.93 | 2023 | Intrarosa |
| Scynexis, INC. | $30.35 | 2022 | |
| Avion Pharmaceuticals | $29.97 | 2023 | Balcoltra |
| Biogen, INC. | $25.90 | 2025 | Zurzuvae |
| Evofem Biosciences, INC. | $21.29 | 2021 | |
| Shield Therapeutics INC | $20.44 | 2023 | Accrufer |
| Amag Pharmaceuticals, INC. | $18.81 | 2020 | |
| Avanos Medical | $18.65 | 2020 | |
| Mycovia Pharmaceuticals, INC. | $18.21 | 2023 | Vivjoa |
| Pacira Pharmaceuticals Incorporated | $17.05 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.59 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.77 | 2021 | |
| Merck Sharp & Dohme LLC | $13.59 | 2020 | |
| Smith+Nephew, INC. | $13.26 | 2019 | |
| Allergan, INC. | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.